Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company’s Expanded ADC Pipeline

Rhea-AI Summary

Akari Therapeutics (Nasdaq: AKTX) CEO Abizer Gaslightwala joined a Virtual Investor “What This Means” interview on Feb. 11, 2026 to discuss the company’s expanded ADC pipeline, a recent patent filing, and the introduction of second ADC candidate AKTX-102 targeting CEACAM5 tumors.

The segment reviewed the scalability of Akari’s PH1-powered ADC platform, the company’s differentiated CEACAM5 antibody construct, execution priorities for lead program AKTX-101 as it advances toward IND and CTA submissions, and the strategic role of a growing patent estate to support partnering and long-term value creation.

Argus Feb 11 session

+1.45% close to close Open Argus

Details

News Market Reaction – AKTX

On Feb 11, the day this news came out, AKTX closed 1.45% above the previous close.

Data tracked by StockTitan Argus for the Feb 11 session.

Key Figures

ADSs registered for resale: 34,680,906 ADSs Outstanding ADSs: 45,781,350 ADSs Potential warrant proceeds: $8.9 million +5 more

ADSs registered for resale

34,680,906 ADSs

Amount registered in S-1 for resale by existing investors

Outstanding ADSs

45,781,350 ADSs

ADSs outstanding as of January 22, 2026 per S-1

Potential warrant proceeds

$8.9 million

Gross proceeds if specified warrants are fully exercised for cash

Cash balance

about $2.5 million

Cash at September 30, 2025 disclosed in S-1

Registered direct gross proceeds

$3,899,997

Gross proceeds from December 17, 2025 registered direct offering

Registered direct net proceeds

approximately $3.3 million

Net proceeds after fees from December 17, 2025 offering

Nasdaq compliance deadline

May 25, 2026

Deadline to regain $1.00 minimum bid price per Nasdaq notice

ADSs sold in offering

10,043,774 ADSs

Number of ADSs sold in December 2025 registered direct deal

Historical Context

5 past events · Latest: Feb 05

5 events

1. Feb 05

   Investor webinar

   24h Move

   -2.2%

   Corporate overview of ADC platform and AKTX-101/102 development plans.

2. Jan 26

   Patent & pipeline

   24h Move

   -0.5%

   Filed key patent and introduced second ADC program AKTX-102 targeting CEACAM5.

3. Jan 09

   CEO strategy update

   24h Move

   -0.3%

   CEO Corner review of 2025 progress and clinical transition plans for 2026.

4. Jan 08

   Conference presentation

   24h Move

   -1.7%

   Announcement of in-person presentation at 2026 Biotech Showcase.

5. Dec 30

   Year-end letter

   24h Move

   +2.3%

   End-of-year letter detailing PH1-based ADC progress and 2026 IND plans.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

antibody drug conjugates, adcs, rna-splicing payloads, cta, +3 more

7 terms

antibody drug conjugates medical

"an oncology biotechnology company pioneering next-generation antibody drug conjugates (ADCs)"

Antibody drug conjugates are targeted medicines that combine an antibody, which seeks out specific markers on diseased cells, with a powerful drug that is released only when the antibody binds its target. Think of it as a guided missile that delivers a toxic payload directly to its target, reducing damage to healthy cells; investors watch them because successful ADCs can offer high-value, niche treatments and drive strong revenue and patent-based protection for developers.

adcs medical

"next-generation antibody drug conjugates (ADCs) powered by novel RNA-splicing payloads"

Antibody-drug conjugates (ADCs) are targeted cancer medicines that combine an antibody, which seeks out specific markers on tumor cells, with a powerful drug payload that is released once the antibody binds its target. Think of them as a guided missile that delivers a toxic package directly to diseased cells to limit harm to healthy tissue. Investors watch ADC news closely because clinical trial results, manufacturing complexity and regulatory decisions can sharply change a biotech company’s value.

rna-splicing payloads medical

"pioneering next-generation antibody drug conjugates (ADCs) powered by novel RNA-splicing payloads"

RNA-splicing payloads are therapeutic molecules carried into cells to change how a gene’s messages are cut and stitched before they make proteins, much like providing new editing instructions to a recipe so it yields a different dish. Investors care because this approach can target diseases caused by faulty gene messages and offers potential for precision treatments, but its commercial value depends on how well the payloads can be delivered, tolerated, and scaled.

cta regulatory

"its planned IND and CTA submissions as it advances towards first-in-human studies"

A CTA (Commodity Trading Advisor) is a professional or firm that manages and advises clients on trading futures, options and other derivatives, similar to a coach who designs and runs strategies using these instruments. It matters to investors because CTAs make decisions that can affect portfolio risk and returns, and they operate under regulatory oversight, so knowing a CTA’s strategy, performance and compliance helps assess potential reward and risk.

first-in-human medical

"as it advances towards first-in-human studies"

A first-in-human study is the initial test of a new drug, medical device, or therapy in people to check safety, side effects and appropriate dosing. It matters to investors because it marks a major development milestone: successful early human testing can reduce scientific and regulatory uncertainty, much like moving a prototype from the workshop to a real-world test drive, and often affects a company’s valuation and funding prospects.

ceacam5 medical

"second ADC pipeline candidate targeting CEACAM5-expressing solid tumors"

A protein found on certain cells and released into the blood that often becomes elevated in some cancers; it is commonly measured as a tumor marker. Think of it as a biological flag or smoke signal that can help doctors detect, monitor disease progression, or judge whether a therapy is working. For investors, levels and uses of this marker matter because they influence diagnostics, drug development, patient selection, regulatory decisions, and commercial markets.

spliceosome-modulating payload medical

"combined with the PH1 spliceosome-modulating payload, as well as the Company’s execution priorities"

A spliceosome-modulating payload is a drug component designed to change how a cell’s RNA-editing machinery (the spliceosome) cuts and pastes genetic messages, altering which proteins the cell makes. Think of it as a targeted instruction that rewrites a factory’s blueprint pages to stop harmful behavior or trigger cell death. For investors, such payloads can mean novel, potentially precise treatments with distinct clinical promise, but they also carry development, safety and regulatory risks tied to altering fundamental cell processes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CEO Abizer Gaslightwala discusses the Company’s recent announcement around its ADC pipeline expansion and IP strategy

Company also discusses its lead ADC program, AKTX-101, and its planned IND and CTA submissions as it advances towards first-in-human studies

Watch the “What This Means” video here

TAMPA, Fla. and LONDON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company pioneering next-generation antibody drug conjugates (ADCs) powered by novel RNA-splicing payloads, today announced that Abizer Gaslightwala, CEO of Akari Therapeutics, participated in a Virtual Investor “What This Means” interview focused on the Company’s expanding ADC pipeline and intellectual property strategy.

As part of the segment, Mr. Gaslightwala discussed Akari’s recently announced patent filing and the introduction of AKTX-102, the Company’s second ADC pipeline candidate targeting CEACAM5-expressing solid tumors. The discussion highlighted how this milestone underscores the scalability of Akari’s PH1-powered ADC platform and its ability to generate multiple differentiated therapeutic programs.

Mr. Gaslightwala also addressed Akari’s differentiated approach to CEACAM5 through its novel antibody construct combined with the PH1 spliceosome-modulating payload, as well as the Company’s execution priorities as its lead program, AKTX-101, advances toward IND and CTA submission and first-in-human studies. In addition, the segment explored the strategic importance of Akari’s growing patent estate in supporting long-term value creation and potential partnering opportunities.

The Virtual Investor “What This Means” segment featuring Akari Therapeutics is now available here.

About Akari Therapeutics
Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune system to drive robust and durable activity. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, FGFR3 fusions, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by late 2026/early 2027, and is also advancing AKTX-102, an ADC against a novel target highly relevant in GI and lung cancers. For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements 
This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the ability of the Company to advance its product candidates for the treatment of cancer and any other diseases, and ultimately bring therapies to patients. These statements are based on the Company’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the Company’s need for additional capital; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the business; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of the Company’s programs or product candidates; risks related to any loss of the Company’s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company’s product candidates, including as a result of potential tariffs; the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company’s product candidates; risks related to competition for the Company’s product candidates; and the Company’s ability to successfully develop or commercialize its product candidates. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release except as required by law.

Investor Relations Contact

JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Akari Therapeutics (AKTX) say about AKTX-101 in the Feb 11, 2026 investor interview?

Akari said AKTX-101 is advancing toward IND and CTA submissions as a near-term clinical priority. According to Akari Therapeutics, management emphasized execution priorities and timelines as the program moves toward first-in-human studies and regulatory filings.

What is AKTX-102 and how does it expand Akari Therapeutics' pipeline (AKTX)?

AKTX-102 is the company’s second ADC candidate targeting CEACAM5-expressing solid tumors. According to Akari Therapeutics, the program demonstrates scalability of the PH1-powered ADC platform and adds a differentiated CEACAM5-directed construct to the pipeline.

How did Akari describe the role of its PH1 spliceosome-modulating payload in the Feb 11, 2026 interview?

Akari described the PH1 payload as a core differentiator enabling multiple ADC programs with novel mechanisms. According to Akari Therapeutics, PH1 supports generation of differentiated therapeutics and underpins the company’s ability to scale its ADC platform.

What did Akari Therapeutics say about its recent patent filing and IP strategy (AKTX)?

Akari highlighted a recent patent filing and expanding patent estate intended to support long-term value and partnering. According to Akari Therapeutics, the growing IP portfolio is strategic for protecting platform innovations and enabling potential collaborations.

Where can investors watch the Akari Therapeutics (AKTX) Virtual Investor "What This Means" segment?

The company made the Virtual Investor segment available online for on-demand viewing. According to Akari Therapeutics, the interview featuring CEO Abizer Gaslightwala is now accessible via the company’s investor video resources for further details.